4月14日,辉瑞宣布终止开发口服GLP-1激动剂Danuglipron(PF-06882961),该药物此前正在研究用于慢性体重管理。这是辉瑞在GLP-1减重药上的再次折戟。此前,辉瑞先后叫停了Danuglipron(每日2次)、Lotiglipron 两项口服GLP-1制剂的研究。缺乏有效的药物来治疗肥胖是过去几十年的一大问题,GLP-1的出现一度改变了这个情况。但是,GLP-1虽然可以降低食欲...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.